Form 4: Regeneron Director Acquires Stock & Options

Regeneron Pharmaceuticals Director David P. Schenkein reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options.

Summary

• David P. Schenkein, a Director at Regeneron Pharmaceuticals, Inc. (REGN), reported changes in his beneficial ownership.
• On January 2, 2026, Schenkein acquired 155 shares of common stock in the form of time-based vesting restricted stock units.
• He also acquired 1,962 non-qualified stock options with an exercise price of $772.76 per share.
• The options will become partially exercisable on the date of the Issuer's first annual meeting following the grant date, with the remainder exercisable on the first anniversary of the grant date, and expire on January 2, 2036.
• Following these transactions, Schenkein beneficially owns 603 shares of common stock directly and 1,962 derivative securities (non-qualified stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports routine insider compensation, which is generally viewed as a neutral to slightly positive event as it aligns director interests with shareholders. There are no unexpected positive or negative financial results or strategic announcements.

Positives

• Director David P. Schenkein acquired 155 restricted stock units, aligning his interests with shareholders.
• The grant of 1,962 non-qualified stock options provides an incentive for future performance, with an exercise price of $772.76.

Future Outlook

The acquired restricted stock units are subject to time-based vesting. The non-qualified stock options will become partially exercisable on the date of the Issuer's first annual meeting following the grant date, with the remainder becoming exercisable on the first anniversary of the grant date, providing future equity incentives.

Industry Context

The acquisition of restricted stock units and stock options by a director is a standard practice for executive and director compensation in the pharmaceutical industry, aiming to align leadership interests with long-term shareholder value. This type of equity grant is common for companies like Regeneron Pharmaceuticals, which rely on long-term strategic development and innovation.

Comparison to Industry Standards

• Compensation structures involving equity grants such as restricted stock units and stock options are standard across the biotechnology and pharmaceutical sectors for directors and executives.
• For example, companies like Amgen (AMGN), Gilead Sciences (GILD), and Pfizer (PFE) routinely use similar mechanisms to incentivize their leadership.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar market capitalization and performance within the industry, reflecting the director's role and contributions.
• Without specific compensation committee reports or peer group analysis, a direct quantitative comparison is not feasible from this Form 4 alone.

Related Party Transactions

• The acquisition of equity by a director is a form of compensation and can be considered a related party transaction in the context of corporate governance, as it involves a transaction between the company and an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially fostering more shareholder-centric decision-making.

Next Steps

• The restricted stock units will vest over time.
• The non-qualified stock options will become exercisable according to their vesting schedule, with a portion exercisable after the next annual meeting and the remainder on the first anniversary of the grant date.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, insider transaction, beneficial ownership, stock options, restricted stock units, director compensation, equity grant